Company Interview / Lumos lighting up in the US

Key points:

Lumos is conducting trials for its fibrotic test to enter the US primary care market.They are collaborating with Hologic on advancing women's health diagnostics.Achieving FDA clearance is key to Lumos reaching profitability and expanding market access.

Doug Ward of Lumos Diagnostics (ASX: LDX) shares insights on the company's progress. Lumos is expanding its reach in the US with the FebriDx® test, targeting a $1 billion market opportunity. Doug mentions the clinical trial for FDA clearance is progressing well.

The test differentiates between bacterial and viral infections, potentially reducing unnecessary antibiotic use by 40%. Currently restricted to professional settings, there's a large potential for primary care rollout. Doug also highlights Lumos's work with Hologic on women's health diagnostics.

On the financials, Doug mentions a strong half-year result and the potential for profitability with upcoming FDA clearances. Lumos plans to bring rapid women's health tests to the GP office, promising significant improvements in patient care.